International collaboration for genome analysis leads to clues about rare cancer
Researchers have joined together to improve understanding about one of the most rare and lethal types of cancer: adrenocortical carcinoma
News
Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
Inhibition of Antiapoptotic proteins using a BH3 mimetic increases leiomyosarcoma sensitivity to doxorubicin.
What A Toddler And Her Tumor Can Teach Us About Cancer Research
Cancer research is often a long waiting game for patients
Awareness key to improved outcomes in male breast cancer
An interview with Harold J. Burstein, MD, PhD, about the incidence of male breast cancer, why screening is difficult and the latest research.
New compounds may aid in development of targeted therapies for a rare paediatric cancer
Two recently discovered compounds have shown promise in preclinical studies for treating Ewing sarcoma, a rare cancer that predominantly affects children and adolescents.
'Exciting' new genetic test for child cancer patients
It is hoped this will give younger patients access to newer, more personalised medicines and further improve survival rates.
Launch of EMA’s Priority Medicines Scheme (PRIME)
A major step forward for patients and their families that have long been hoping for earlier access to safe treatments for their unmet medical needs
Rare Disease Day: Rare Cancers & Rare Diseases: mapping similarities & difference to improve collaboration
A report highlighting the similarities and differences between patients affected by rare diseases and by rare cancers, or rare diseases leading to cancers
European Reference Networks: Rare Cancers or Forgotten Cancers?
A call for appropriate categorisation of European Reference Networks
SIOPE marks International Childhood Cancer Day
SIOPE's Strategic Plan for a Better Future for Children with Cancer
Daily Telegraph: We need to think about how we fund children's cancer
The perception that research should be funded according to incidence means that individual rare cancers are doomed forever to receive a fraction of the money
FDA approves first drug to show survival benefit in liposarcoma
The FDA approved Halaven for the treatment of liposarcoma that cannot be removed by surgery (unresectable) or is advanced (metastatic).